Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment.
about
Management of non-alcoholic fatty liver disease in 2015Endocrine causes of nonalcoholic fatty liver diseaseNonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment optionsNon-alcoholic fatty liver disease: what has changed in the treatment since the beginning?Lipid-lowering agents in the management of nonalcoholic fatty liver diseaseA randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.Republished: Non-alcoholic fatty liver disease: a practical approach to treatment.A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study.International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].Aliskiren Reduces Hepatic steatosis and Epididymal Fat Mass and Increases Skeletal Muscle Insulin Sensitivity in High-Fat Diet-Fed Mice.Untreated newly diagnosed essential hypertension is associated with nonalcoholic fatty liver disease in a population of a hypertensive center.Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications.Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities.The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study.Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis.NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet.Effects of Azilsartan, Aliskiren or their Combination on High Fat Diet-induced Non-alcoholic Liver Disease Model in Rats.Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis.Non-alcoholic fatty liver disease: a practical approach to treatment.The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease.Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart Study.
P2860
Q26771148-105A6A10-9023-44C1-9636-360DF13BC292Q26780254-AA2BE523-2396-4397-A54A-1747F861480BQ26796448-AE2C7DD5-6EFC-4112-B126-7FE979C8A6F6Q26829503-EAFDD085-1BA6-4192-B9F9-7FB41E710028Q27024352-52219C88-C495-49F5-A94A-7C5130932BD2Q33574413-3E738171-DD94-4B38-ACD3-46353CEC3E4AQ34168532-ADFCE3A6-89FC-47F2-81F3-B0DED7B731B3Q34647400-7EF722D4-99E0-4502-9CBA-5A28275C40FEQ35035662-CB7F800C-B71E-4D04-BE4C-28DC55469BD4Q35135556-BA933769-658E-4596-9799-919A92341610Q35855651-0F2D2085-503C-4400-B41F-23BA97174FADQ36241932-49A764A5-FEBB-472F-84EC-85D4B0A75725Q36432343-84641B46-D7E1-4263-B03C-5182F5745C4CQ36473562-30C63DB1-ED1C-4FFE-BB12-53A5489D1C4EQ37385527-1C38FAB6-A2BF-4C49-A4F4-B1AE7911CD9AQ38212215-B2329399-B24D-44F1-B572-DADE454B9208Q38664843-88EB57DE-FEF7-4EAF-AEED-841C40B7D427Q38782562-CB7E29FF-A6AE-4892-9146-930D23671AF9Q38867031-4F02C10F-89B8-4A46-B5C0-33FBEFE24876Q41761865-369FCC97-75FB-41C5-BB28-D8595FF12060Q42072118-31A5F3C5-428E-447C-B61C-B7B7BA6BEDDDQ42354239-CC2212B7-A09E-42FC-90C0-2E6CA77885D6Q42365504-F010BDE3-796F-4560-86A9-48CEBEC8B63FQ42913256-10EB25CC-75B0-4B39-9CE0-48B8B8B9FA08Q49190671-D97A5FAF-1DE5-4400-9325-0C51BB160A39Q53714410-7C6F6261-B7C7-4332-BF05-7899CD101028
P2860
Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Nonalcoholic fatty liver disea ...... m: Implications for treatment.
@en
Nonalcoholic fatty liver disea ...... m: Implications for treatment.
@nl
type
label
Nonalcoholic fatty liver disea ...... m: Implications for treatment.
@en
Nonalcoholic fatty liver disea ...... m: Implications for treatment.
@nl
prefLabel
Nonalcoholic fatty liver disea ...... m: Implications for treatment.
@en
Nonalcoholic fatty liver disea ...... m: Implications for treatment.
@nl
P2860
P356
P1476
Nonalcoholic fatty liver disea ...... m: Implications for treatment.
@en
P2093
Konstantinos Tziomalos
Paschalis Paschos
P2860
P304
P356
10.4254/WJH.V4.I12.327
P577
2012-12-01T00:00:00Z